In response to the BMJ article 'Independent researchers should have right to publish trial results if original researchers don’t, campaigners say' published on 14 June 2013, the ABPI has issued the following statement.
The ABPI is a strong advocate of transparency in clinical research information and have already hosted, and been engaged in, workshops to explore how research data can be better made available for the purpose of further research. We are actively involved in discussions with our members and stakeholders at national, European and global levels on this important issue and we would be interested in discussing this particular new initiative further with those involved.
In line with our Code of Practice, companies are required to publish all clinical trial results within one year of marketing authorisation and new clinical trials must be publically registered within 21 days of the first patient being enrolled. Many of our companies already provide clinical research information to researchers, while taking into consideration the practicalities, patient confidentiality and protection of personal data; and respecting commercially confidential information so that the research and development of new medicines is not disincentivised.
ABPI Press OfficeTel: +44 (0) 20 7747 1439 or +44 (0) 20 7747 1436Mobile: +44 (0) 7808 641810 or +44 (0) 7920 597 923 Email: firstname.lastname@example.org
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.